http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 14 Jul 2024 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Hot+List/How+AI+is+transforming+radiotherapy+%E2%80%93+BofA/23460883.html <p>As part of a series on radiotherapy, BofA analysts have published a report describing the ways in which artificial intelligence (AI) is transforming screening, treatment, monitoring and the overall decision-making process.</p><p>One of the biggest limitations of the traditional approach in radiotherapy and existing scanning methods is that they capture only a ‘snapshot in time,’ so that tumor micromovements cannot be accounted for, with inefficient weekly rescanning being the only solution. Based on their research, BofA analysts believe AI can increase precision and efficiency, leading to safer and more effective treatment.</p><p>“The modern RT workflow has remained unchanged for the past several http://www.streetinsider.com/Hot+List/How+AI+is+transforming+radiotherapy+%E2%80%93+BofA/23460883.html Sun, 14 Jul 2024 08:00:00 -0400 IXJ http://www.streetinsider.com/Hot+List+Pro/How+AI+is+transforming+radiotherapy+%E2%80%93+BofA/23460883.html <p>As part of a series on radiotherapy, BofA analysts have published a report describing the ways in which artificial intelligence (AI) is transforming screening, treatment, monitoring and the overall decision-making process.</p><p>One of the biggest limitations of the traditional approach in radiotherapy and existing scanning methods is that they capture only a ‘snapshot in time,’ so that tumor micromovements cannot be accounted for, with inefficient weekly rescanning being the only solution. Based on their research, BofA analysts believe AI can increase precision and efficiency, leading to safer and more effective treatment.</p><p>“The modern RT workflow has remained unchanged for the past several http://www.streetinsider.com/Hot+List+Pro/How+AI+is+transforming+radiotherapy+%E2%80%93+BofA/23460883.html Sun, 14 Jul 2024 08:00:00 -0400 IXJ http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html <p>The estimated $1.6 trillion global pharmaceutical industry is set to witness substantial revenue growth through 2027 despite headwinds including biosimilar competition, Medicare price negotiation, and products losing exclusivity.</p><p>While Big Pharma is expected to benefit the most, even the generic drug industry is expected to witness lower levels of price erosion and see a return to moderate revenue growth, according to a recent report by S&P Global. Further, only a moderate level of mergers and acquisitions are anticipated in the sector.</p><p>Organic revenue growth in large global pharma companies is largely being driven by medical advancements in areas including oncology, immunology, neurology http://www.streetinsider.com/Hot+List+Pro/Top+pharma+stocks+to+own+in+2024+%E2%80%93+Citi/22941108.html Sun, 17 Mar 2024 20:00:00 -0400 ABBV ALNY AXSM IMVT IXJ LEGN LLY MRK http://www.streetinsider.com/Analyst+Comments/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html si-local-file:///var/storage/newsbody/2021/0406/18226610.html http://www.streetinsider.com/Analyst+Comments/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html Tue, 06 Apr 2021 08:14:42 -0400 IXJ SPY XLF http://www.streetinsider.com/Analyst+Comments/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html si-local-file:///var/storage/newsbody/2021/0406/18226610.html http://www.streetinsider.com/Analyst+Comments/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html Tue, 06 Apr 2021 08:14:42 -0400 IXJ SPY XLF http://www.streetinsider.com/Analyst+Comments/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html si-local-file:///var/storage/newsbody/2021/0406/18226610.html http://www.streetinsider.com/Analyst+Comments/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html Tue, 06 Apr 2021 08:14:42 -0400 IXJ SPY XLF http://www.streetinsider.com/Trader+Talk/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html si-local-file:///var/storage/newsbody/2021/0406/18226610.html http://www.streetinsider.com/Trader+Talk/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html Tue, 06 Apr 2021 08:14:42 -0400 IXJ SPY XLF http://www.streetinsider.com/Trader+Talk/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html si-local-file:///var/storage/newsbody/2021/0406/18226610.html http://www.streetinsider.com/Trader+Talk/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html Tue, 06 Apr 2021 08:14:42 -0400 IXJ SPY XLF http://www.streetinsider.com/Trader+Talk/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html si-local-file:///var/storage/newsbody/2021/0406/18226610.html http://www.streetinsider.com/Trader+Talk/Health+Care+and+Financials+Led+Equities+Selling+Last+Week%2C+BofA%27s+Weekly+Flows+Show/18226610.html Tue, 06 Apr 2021 08:14:42 -0400 IXJ SPY XLF http://www.streetinsider.com/Press+Releases/BlackRock+Announces+Share+Split+for+Four+iShares+ETFs/14001991.html si-local-file:///var/storage/newsbody/2018/0329/14001991.html http://www.streetinsider.com/Press+Releases/BlackRock+Announces+Share+Split+for+Four+iShares+ETFs/14001991.html Thu, 29 Mar 2018 16:30:00 -0400 BLK DVY EEMA ESGE IGOV IOO IXJ KXI